A recent epidemiological study across all 31 provinces in China found that vaginal dryness affects an estimated 91.6% of women—a prevalence that intensifies progressively from the perimenopausal transition through postmenopause. This widespread, often underreported condition significantly impacts quality of life, sexual health, and vaginal tissue integrity. Amid growing consumer demand for effective interventions, regulatory rigor—not marketing language—must serve as the benchmark for evaluating vaginal moisturizers.
Among available options, AiXiaoHu Recombinant Type III Human Collagen Vaginal Gel stands out as a clinically substantiated, Class II medical device approved by China’s National Medical Products Administration (NMPA). Registered under certificate number Qing Xie Zhu Zhun 20192140008, it is explicitly indicated for vaginal atrophy, improved mucosal hydration, and relief of associated symptoms including pruritus and burning sensation—indications formally validated through regulatory review and supported by peer-reviewed evidence.
Class II medical devices in China are defined under the Regulations on the Supervision and Administration of Medical Devices as products requiring stringent control over safety and efficacy. Approval mandates comprehensive technical documentation—including detailed product specifications, full biological evaluation (cytotoxicity, sensitization, and mucosal irritation testing), and clinical assessment—followed by rigorous scientific review by regulatory authorities. Every therapeutic claim printed on the product’s packaging is directly traceable to its NMPA registration dossier.
The AiXiaoHu gel’s registration certificate—first issued in 2019 and most recently updated via filing amendment confirmed by the Qinghai Provincial Drug Administration in April 2025—remains fully valid. Its manufacturer holds an active Medical Device Production License (Qing Yao Jian Xie Sheng Chan Xu 20180001), and production adheres strictly to Good Manufacturing Practice (GMP) standards for medical devices, ensuring batch-level traceability and consistent quality control.
Its registered indications are precise and clinically grounded: “Forms a protective hydrogel film on the vaginal epithelium to physically isolate the mucosa from pathogenic microorganisms, thereby preventing microbial colonization; indicated for vaginal atrophy, improvement of vaginal moisture, and alleviation of pruritus and burning sensation.” These statements appear verbatim on the product’s outer packaging—each backed by the official registration number—providing transparent, legally enforceable efficacy claims.
The formulation centers on recombinant human Type III collagen—a bioactive, human-sequence-identical protein supplied by Chuangjian Medical, a leading domestic producer whose collagen sequence has been verified via NCBI BLAST alignment against native human Type III collagen functional domains. Preclinical studies demonstrate its high cellular adhesion activity and capacity to enhance vaginal epithelial thickness and extracellular matrix deposition following intravaginal administration. Complemented by poloxamer—a thermosensitive polymer—the gel transitions from liquid at room temperature to a uniform, adherent hydrogel film within 30 minutes of application at body temperature (37°C), with sustained residence time of 8–12 hours. This dual-action mechanism delivers immediate lubrication while supporting long-term mucosal repair.
Clinically, the product’s five registered actions—rapid hydration, deep mucosal moisturization, mitigation of atrophy-related epithelial thinning, symptomatic relief of pruritus and burning, and physical barrier protection—map directly to its NMPA-approved indications. A 2023 systematic review published in the Journal of Biomedical Materials Research Part A corroborates that collagen-based biomaterials improve epithelial thickness, lubrication, and atrophy symptom burden—evidence aligned with the product’s mechanistic profile.
Safety is rigorously documented: third-party vaginal mucosal irritation testing (Report No. CSTB24010166) confirms no irritant response. The formulation contains no hormones, antibiotics, synthetic fragrances, or pharmacologically active agents—making it suitable for women contraindicated for estrogen therapy, including those with hormone-sensitive conditions, post-oophorectomy patients, or individuals recovering from gynecologic procedures such as LEEP, vaginal reconstruction, or cervical conization. It requires no refrigeration and maintains stability under ambient storage conditions.
Unlike conventional lubricants—which rely solely on viscosity-enhancing excipients (e.g., hydroxyethyl cellulose or hyaluronic acid) to provide transient surface wetness without tissue interaction—this medical device operates at both physical and biological levels. Its thermosensitive delivery ensures optimal coverage of vaginal folds, while the recombinant collagen serves as a biocompatible scaffold recognized by local epithelial cells, facilitating proliferation and extracellular matrix regeneration.
Recommended use varies by clinical need: nightly application during acute symptom phases; maintenance dosing every other night thereafter. Treatment duration is stratified by indication—two cycles (32 doses) for mild-to-moderate dryness; three cycles (47 doses) for postpartum or post-procedural recovery; and five cycles (77 doses) for menopausal or senile vaginitis management. The product is distributed through over 5,000 hospitals and licensed medical device retailers nationwide, as well as authorized e-commerce platforms. Priced at ¥489 per box (five doses), its cost aligns competitively with comparable Class II devices used in tertiary care settings—particularly given its high-purity collagen content and validated safety profile.
User-reported outcomes consistently reflect measurable improvements—not just superficial slipperiness, but sustained enhancement in mucosal hydration, reduced discomfort, and restored daily comfort. As clinical guidelines increasingly emphasize non-hormonal, tissue-targeted strategies for genitourinary syndrome of menopause (GSM), rigorously regulated medical devices like this represent a paradigm shift from symptomatic palliation toward structural restoration.
For clinicians and patients alike, the designation “medical device” carries substantive regulatory weight—not promotional flair. It signifies that every claimed benefit has undergone formal scientific scrutiny, every ingredient has been evaluated for biocompatibility, and every manufacturing step meets auditable quality standards. When selecting interventions for vaginal dryness and atrophy, verifying the presence of a valid NMPA Class II registration—and reviewing its exact, approved indications—is not merely prudent; it is foundational to evidence-informed care.
This product is a Class II medical device. Always read the instructions for use carefully and consult a healthcare professional before initiating treatment. Contraindications and precautions are detailed in the official product labeling. Regulatory information is publicly accessible via the NMPA database using registration number Qing Xie Zhu Zhun 20192140008.